Based in Chicago, Illinois, AveXis is a clinical-stage gene therapy company developing innovative treatments for rare and life-threatening genetic diseases.  Our gene therapy product candidate, scAAV9.CB.SMN (AVXS 101), is currently in a Phase 1 clinical trial in the United States for the treatment of spinal muscular atrophy (SMA) type 1.  SMA is the most common cause of genetic infant mortality and the second most common autosomal recessive disease.  No treatment is currently approved for the treatment of SMA in the United States, Europe or other geography.  The SMA program has received Orphan Drug designation in both the United States and Europe.
 
AveXis is a rapidly growing leader among gene therapy biotech companies and continues to establish relationships with academics, biotechnology and pharmaceutical companies, and healthcare investors.
Company Growth (employees)
Type
Private
HQ
Bannockburn, US
Size (employees)
96 (est)+24%
Website
avexis.com
AveXis is headquartered in Bannockburn, US

AveXis Office Locations

AveXis has an office in Bannockburn
Bannockburn, US (HQ)
160 2275 Half Day Rd

AveXis Metrics

Summary Metrics

AveXis's latest funding round in September 2015 was reported to be $65 m. In total, AveXis has raised $75 m

AveXis Financial Metrics

Net income (2016)

($83 m)

Cash (31-Dec-2016)

$240.4 m
FY, 2016

R&D expense

$58.9 m

General and administrative expense

$24.5 m

Operating expense total

$83.4 m

EBIT

($83.4 m)

Interest income

$402.8 k

Net Income

($83 m)
FY, 2016

Cash

$240.4 m

Current Assets

$245.2 m

PP&E

$24.2 m

Total Assets

$270.6 m

Current Liabilities

$24.4 m

Preferred Stock

$309

Additional Paid-in Capital

$387.7 m

Retained Earnings

($141.6 m)

Total Equity

$246.1 m

Financial Leverage

1.1 x
FY, 2016

Net Income

($83 m)

Depreciation and Amortization

$64.6 k

Accounts Payable

$163.9 k

Cash From Operating Activities

($48 m)

Capital Expenditures

($19.2 m)

Cash From Investing Activities

($19.2 m)

Cash From Financing Activities

$245.4 m

Interest Paid

$14.7 k

Free Cash Flow

($67.2 m)

AveXis Online Presence

AveXis Company Life

You may also be interested in